A5017238829- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
- Language Development and Disorders
- Vaccine Coverage and Hesitancy
- Reading and Literacy Development
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- COVID-19 Impact on Reproduction
- Influenza Virus Research Studies
- Maternal Mental Health During Pregnancy and Postpartum
- COVID-19 and healthcare impacts
- Reproductive System and Pregnancy
- COVID-19 epidemiological studies
- Hearing Impairment and Communication
- Health, Environment, Cognitive Aging
- Stress Responses and Cortisol
- Genetic and phenotypic traits in livestock
- Stuttering Research and Treatment
- Birth, Development, and Health
- Neuroendocrine regulation and behavior
- Pregnancy and Medication Impact
- Autism Spectrum Disorder Research
- Genomics and Phylogenetic Studies
- Hearing Loss and Rehabilitation
- Genetics and Neurodevelopmental Disorders
Centers for Disease Control and Prevention
2023-2024
National Center for Immunization and Respiratory Diseases
2023-2024
Yale University
2024
Vanderbilt University Medical Center
2024
Intermountain Healthcare
2024
Kaiser Permanente
2024
Atrium Health Wake Forest Baptist
2024
Hennepin County Medical Center
2024
Baystate Medical Center
2024
Baylor Scott & White Medical Center - Temple
2024
On September 1, 2022, bivalent COVID-19 mRNA vaccines, composed of components from the SARS-CoV-2 ancestral and Omicron BA.4/BA.5 strains, were recommended by Advisory Committee on Immunization Practices (ACIP) to address reduced effectiveness monovalent vaccines during variant predominance (1). Initial recommendations included persons aged ≥12 years (Pfizer-BioNTech) ≥18 (Moderna) who had completed at least a primary series any Food Drug Administration-authorized or -approved vaccine ≥2...
The SARS-CoV-2 Omicron sublineage XBB was first detected in the United States August 2022.* together with a sublineage, XBB.1.5, accounted for >50% of sequenced lineages Northeast by December 31, 2022, and 52% nationwide as January 21, 2023. COVID-19 vaccine effectiveness (VE) can vary variant; reduced VE has been observed against some variants, although this is dependent on health outcome interest. goal U.S. vaccination program to prevent severe disease, including hospitalization death (1);...
On September 12, 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (updated) COVID-19 vaccination with a monovalent XBB.1.5-derived vaccine for all persons aged ≥6 months to prevent COVID-19, including severe disease. During fall XBB lineages co-circulated JN.1, an Omicron BA.2.86 lineage that emerged in 2023. These variants have amino acid substitutions might increase escape from neutralizing antibodies. predominated through December when JN.1 became...
In this study, the authors determined adolescent speech, language, and literacy outcomes of individuals with histories early childhood speech sound disorders (SSD) without comorbid language impairment (LI) examined factors associated these outcomes.
On June 19, 2022, the original monovalent mRNA COVID-19 vaccines were approved as a primary series for children aged 6 months-4 years (Pfizer-BioNTech) and months-5 (Moderna) based on safety, immunobridging, limited efficacy data from clinical trials. December 9, CDC expanded recommendations use of updated bivalent to ≥6 months. vaccine effectiveness (VE) against emergency department or urgent care (ED/UC) encounters was evaluated within VISION Network during July 4, 2022-June 17, 2023,...
Moderna COVID-19 vaccine primary series consists of two 25 μg doses separated by at least 4-8 weeks.† Pfizer-BioNTech three 3 doses, with 3-8 weeks between 1 and 2 ≥8 3. § At nearly all ICATT sites, test eligibility is restricted to persons aged ≥3 years.Therefore, this analysis was limited children years.¶ registration, caregivers reported the presence any following COVID-19-like illness symptoms: fever, cough, shortness breath, recent loss sense smell or taste, muscle pain, fatigue,...
Purpose Extensive research suggests that maternal prenatal distress is reliably related to perinatal and child health outcomes—which may persist into adulthood. However, basic questions remain regarding mechanisms involved. To better understand these mechanisms, we developed the Understanding Pregnancy Signals Infant Development (UPSIDE) cohort study, which has several distinguishing features, including repeated assessments across trimesters, analysis of multiple biological pathways...
Prenatal maternal infection and anxiety have been linked, in separate lines of study, with child neurodevelopment. We extend integrate these study a large prospective longitudinal cohort Data are based on the Avon Longitudinal Study Parents Children (ALSPAC) cohort; prenatal was assessed from self-report questionnaire; derived reports several conditions pregnancy (n = 7,042). Child neurodevelopment at approximately 8 years age by in-person testing, social communication problems associated...
Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2/BA.2.12.1 and BA.4/BA.5 subvariants have mutations associated with increased capacity to evade immunity when compared prior variants. We evaluated mRNA monovalent booster dose effectiveness among persons ≥5 years old during predominance. Methods A test-negative, case-control analysis included data from 12 148 pharmacy SARS-CoV-2 testing sites nationwide for aged ≥1 disease-2019 (COVID-19)-like symptoms...
Purpose The relationship between phonological awareness, overall language, vocabulary, and nonlinguistic cognitive skills to decoding reading comprehension was examined for students at 3 stages of literacy development (i.e., early elementary school, middle high school). Students with histories speech sound disorders (SSD) without language impairment (LI) were compared SSD or LI (typical language; TL). Method In a cross-sectional design, ages 7;0 (years;months) 17;9 completed tests that...
Purpose The goal of this study was to determine whether adolescent outcomes for individuals with histories early speech sound disorders (SSD) could be differentiated by and language skills at earlier ages (preschool, 4–6 years, school age, 7–10 years). Method used a retrospective longitudinal design. Participants without SSD were classified in adolescence as having no SSD, resolved low multisyllabic word (MSW; difficulty MSW repetition but errors conversational speech), or persistent (errors...
A major milestone of child development is the acquisition and use speech language. Communication disorders, including sound disorder (SSD), can impair a child's academic, social behavioral development. Speech complex, polygenic trait with substantial genetic component. However, specific genes that contribute to SSD remain largely unknown. To identify associated genes, we assessed association DYX2 dyslexia risk locus markers in neurochemical signaling (e.g., nicotinic dopaminergic) related...
Speech sound disorder (SSD) is one of the most common communication disorders, with a prevalence rate 16% at 3 years age, and an estimated 3.8% children still presenting speech difficulties 6 age. Several studies have identified promising associations between disorders genes in brain neuronal pathways; however, there been few focusing on SSD its associated endophenotypes. On basis hypothesis that may influence endophenotypes to we focused three related central nervous system functioning:...
BACKGROUND AND OBJECTIVES Understanding the real-world impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mitigation measures, particularly vaccination, in children and adolescents congregate settings remains important. We evaluated protection against SARS-CoV-2 infection using school-based testing data. METHODS Using data from Utah middle- high-school students participating school-wide antigen January 2022 during omicron (BA.1) variant predominance, log binomial models...
Abstract Pregnant people face increased risk of severe COVID-19. Current guidelines recommend updated COVID-19 vaccination (2023–2024) for those aged ≥6 months, irrespective pregnancy status. To refine recommendations pregnant people, further data are needed. Using a test-negative design, we evaluated vaccine effectiveness against medically attended with COVID-19–like illness among 18 to 45 years during June 2022 August 2023. When doses were received pregnancy, was 52% (95% CI, 29%–67%);...
On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of monovalent vaccines during SARS-CoV-2 Omicron variant predominance.
Abstract Background Pregnant people have an increased risk of severe COVID-19, including hospitalization and critical illness. Currently, pregnant are recommended to receive the same vaccinations as non-pregnant age underlying health status (i.e., with or without immunocompromising conditions); however, additional data needed inform policy decisions around potential need for extra dose during pregnancy protect mother infant. Our goal was estimate effectiveness COVID-19 vaccination against...